Browsing tag:

high blood pressure


On September 10, 2014, The U.S. Food and Drug Administration (US FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) for anti-obesity treatments in combination with a reduced-calorie diet and exercise. Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California. The FDA approved the[…]

Read More

Approximately four million Americans undergo cataract surgery every year, so the recent FDA approval of Ketorolac and Phenylephrine on June 2, 2014 is timely and beneficial for many patients in the United States. Known as the brand name Omidria, the combination of Ketorolac and Phenylephrine to create an efficacious pupil-dilating agent has been deemed successful[…]

Read More

Known as the brand name Lotrel, the combination of amlodipine besylate and benazepril is a powerful calcium channel blocker. The patent for this formidable medication marketed by Novartis expires on December 19, 2017, paving the way for a generic version of this blockbuster drug. With roughly one in three U.S. adults suffering from high blood[…]

Read More

Valsartan  is used as a treatment for high blood pressure, as well as congestive heart failure. As part of a class of medications called angiotensin II receptor antagonists, valsartan impedes the action of natural substances in the body that cause a tightening of blood vessels, thus allowing a smoother blood flow to the heart. Also[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service